Viking Therapeutics (VKTX) Cash from Financing Activities (2014 - 2026)

Viking Therapeutics has reported Cash from Financing Activities for 13 years, with the latest figure at $23.6 million in Q2 2026.

• Quarterly Cash from Financing Activities rose 4552.07% year-over-year to $23.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $111.2 million (up 2441.02% YoY) and the FY2025 annual result came in at $76.4 million, down 87.52% from the prior year.
• Cash from Financing Activities rose to $23.6 million in Q2 2026 per VKTX's latest filing, from $12.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $606.0 million in Q1 2024 and troughed at -$5.0 million in Q1 2022.
• A 5-year average of $55.6 million and a median of $1.8 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities jumped 22770.21% in 2022, then plunged 840.0% in 2023.
• Over 5 years, Cash from Financing Activities stood at $10.7 million in 2022, then sank by 98.25% to $188000.0 in 2023, then surged by 431.91% to $1.0 million in 2024, then jumped by 7410.3% to $75.1 million in 2025, then tumbled by 68.6% to $23.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $23.6 million, $12.1 million, and $75.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.